A comprehensive review of prostate cancer screening studies has found that PSA (prostate-specific antigen) blood tests likely reduce the risk of death from the disease, marking a significant shift in medical evidence after years of discouragement. The Cochrane review, published in May 2026, analyzed data from six large trials involving 800,000 participants across Europe and North America, finding that screening prevented approximately two prostate cancer deaths for every 1,000 men tested.

Why Did Doctors Stop Recommending PSA Tests?

For nearly two decades, PSA screening fell out of favor in the medical community. After being widely adopted in the 1990s, major organizations including the U.S. Preventive Services Task Force (USPSTF) discouraged its use starting in 2008 for men 75 and older, then for all men in 2012. The reason was straightforward: earlier research couldn't prove that screening saved lives, and the test was known to cause real harm.

PSA screening led to overdiagnosis and overtreatment of slow-growing cancers that would never have threatened a man's life. The consequences were serious. Prostate biopsies carry a high risk of infection, while surgery to remove tumors can cause erectile dysfunction, and radiation therapy brings other life-altering side effects. Roughly half of prostate cancers diagnosed in the United States don't warrant aggressive treatment and are better managed through monitoring alone.

What Changed in the New Research?

The updated Cochrane review contains substantially more long-term data than the previous 2013 version, particularly from the European Randomized Study of Screening for Prostate Cancer (ERSPC), which followed participants for up to 23 years. This extended follow-up revealed that PSA screening does provide a measurable benefit in reducing disease-specific deaths, though the absolute benefit remains modest.

"This study is timely because I think it provides sufficient evidence to support that screening could be beneficial if it is offered appropriately to those who are most likely to benefit, and it could actually save lives," said Simpa Salami, a professor of urology at the University of Michigan.

Simpa Salami, Professor of Urology, University of Michigan

Importantly, the medical tools available today have improved significantly since the era of widespread overtreatment. Doctors now use additional biomarkers in urine and blood, as well as MRI imaging, to determine which men with elevated PSA levels actually need biopsies. This refinement helps maximize detection of high-grade, dangerous cancers while minimizing unnecessary diagnosis of slow-growing ones.

How to Approach PSA Screening Wisely

• Have a Conversation with Your Doctor: The Cochrane review emphasizes that men should discuss PSA screening with their physician rather than pursuing it independently. A doctor-patient relationship allows for ongoing monitoring and informed decision-making over time.
• Understand the Real Benefit: Screening prevents approximately one death for every 15 men who would otherwise die from prostate cancer over a 20-year period. This means most men who are screened will not experience a life-saving benefit, though some will.
• Expect Regular Testing, Not One-Time Screening: The benefits observed in research studies came from men who received PSA tests on a regular basis and worked with their physicians to interpret results over time, not from isolated screening events.
• Know Your Risk Factors: Men at higher risk for aggressive prostate cancer, such as those with a family history or African American men, may benefit more from screening discussions with their doctors.

Otis Brawley, a professor of oncology and epidemiology at Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center, stressed the importance of context in interpreting these findings. He noted that the benefits observed in the research trials required consistent medical care and accurate follow-ups, which can be challenging in the American health care system.

"I think the appropriate thing within the doctor-patient relationship is that a doctor ought to offer the test to the patient," Brawley stated, emphasizing that doctors should be clear about both the benefits and the risks of overdiagnosis and overtreatment.

Otis Brawley, Professor of Oncology and Epidemiology, Johns Hopkins University

Brawley also highlighted a critical misunderstanding in American medicine: the expectation that screening should prevent all prostate cancer deaths. "If you have 15 men who are going to die from prostate cancer, screening them in a program of high-quality screening over a period of 20 years will prevent 1 of the 15 men from dying," he explained. This means that even with screening, the majority of men who would die from prostate cancer will still do so, a reality that requires realistic expectations.

The key takeaway from this updated evidence is that PSA screening is not inherently harmful or beneficial; its value depends on how it is implemented. When offered as part of an ongoing relationship with a physician who can monitor results over time and use modern tools to avoid unnecessary biopsies, screening may help some men avoid death from prostate cancer. However, one-time screening events or testing without proper follow-up are unlikely to deliver the same benefits observed in the research trials.

Men interested in prostate cancer screening should schedule a conversation with their doctor to discuss their individual risk factors, the potential benefits and harms, and whether regular PSA testing makes sense for their situation.